That’s the title of a KFF article revealed final week. The outcomes are primarily based on KFF’s 2024 Employer Well being Advantages Survey. They write:
For KFF’s survey of two,142 randomly chosen corporations, officers from these with 500 or extra staff had been requested how a lot of the rebates negotiated by [pharmacy benefit managers] PBMs returned to the corporate as financial savings. About 19% mentioned they acquired many of the rebates, 27% mentioned some, and 16% mentioned little. Thirty-seven % of the respondents didn’t know.Whereas a bigger proportion of officers from the biggest corporations mentioned they received most or a few of the rebates, the solutions — and their distinction with the testimony of PBM leaders — mirror the confusion or ignorance of employers about what their drug profit managers do, mentioned survey chief Gary Claxton, a senior vp at KFF, a well being info nonprofit that features KFF Well being Information.“I don’t assume they’ll ever know all of the methods the cash strikes round as a result of there are such a lot of layers, between the wholesalers and the pharmacies and the producers,” he mentioned…
“Employers are typically pissed off by the shortage of transparency into all the costs on the market,” Claxton mentioned. “They will’t truly know what’s true.”
Do you assume PBMs result in larger or decrease pharmacy value?
